Overview

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Status:
Terminated
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
Phase:
Phase 2
Details
Lead Sponsor:
EusaPharma (UK) Limited
Treatments:
Siltuximab